Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3. European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 "CREATE".

2.50
Hdl Handle:
http://hdl.handle.net/10541/620770
Title:
Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3. European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 "CREATE".
Authors:
Schöffski, P; Wozniak, A; Kasper, B; Aamdal, S; Leahy, Michael G; Rutkowski, P; Bauer, S; Gelderblom, H; Italiano, A; Lindner, L; Hennig, I; Strauss, S; Zakotnik, B; Anthoney, A; Albiges, L; Blay, J; Reichardt, P; Sufliarsky, J; van der Graaf, W; Debiec-Rychter, M; Sciot, R; Van Cann, T; Marréaud, S; Raveloarivahy, T; Collette, S; Stacchiotti, S
Abstract:
Alveolar soft part sarcoma(ASPS) is an orphan malignancy associated with a rearrangement of transcription factor E3(TFE3), leading to abnormal MET gene expression. We prospectively assessed the efficacy and safety of the tyrosine kinase inhibitor(TKI) crizotinib in patients with advanced or metastatic ASPS.
Affiliation:
Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium
Citation:
Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3. European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 "CREATE". 2017 Ann Oncol
Journal:
Annals of Oncology
Issue Date:
5-Dec-2017
URI:
http://hdl.handle.net/10541/620770
DOI:
10.1093/annonc/mdx774
PubMed ID:
29216400
Type:
Article
Language:
en
ISSN:
1569-8041
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorSchöffski, Pen
dc.contributor.authorWozniak, Aen
dc.contributor.authorKasper, Ben
dc.contributor.authorAamdal, Sen
dc.contributor.authorLeahy, Michael Gen
dc.contributor.authorRutkowski, Pen
dc.contributor.authorBauer, Sen
dc.contributor.authorGelderblom, Hen
dc.contributor.authorItaliano, Aen
dc.contributor.authorLindner, Len
dc.contributor.authorHennig, Ien
dc.contributor.authorStrauss, Sen
dc.contributor.authorZakotnik, Ben
dc.contributor.authorAnthoney, Aen
dc.contributor.authorAlbiges, Len
dc.contributor.authorBlay, Jen
dc.contributor.authorReichardt, Pen
dc.contributor.authorSufliarsky, Jen
dc.contributor.authorvan der Graaf, Wen
dc.contributor.authorDebiec-Rychter, Men
dc.contributor.authorSciot, Ren
dc.contributor.authorVan Cann, Ten
dc.contributor.authorMarréaud, Sen
dc.contributor.authorRaveloarivahy, Ten
dc.contributor.authorCollette, Sen
dc.contributor.authorStacchiotti, Sen
dc.date.accessioned2018-01-12T09:18:52Z-
dc.date.available2018-01-12T09:18:52Z-
dc.date.issued2017-12-05-
dc.identifier.citationActivity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3. European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 "CREATE". 2017 Ann Oncolen
dc.identifier.issn1569-8041-
dc.identifier.pmid29216400-
dc.identifier.doi10.1093/annonc/mdx774-
dc.identifier.urihttp://hdl.handle.net/10541/620770-
dc.description.abstractAlveolar soft part sarcoma(ASPS) is an orphan malignancy associated with a rearrangement of transcription factor E3(TFE3), leading to abnormal MET gene expression. We prospectively assessed the efficacy and safety of the tyrosine kinase inhibitor(TKI) crizotinib in patients with advanced or metastatic ASPS.en
dc.language.isoenen
dc.rightsArchived with thanks to Annals of oncology : official journal of the European Society for Medical Oncologyen
dc.titleActivity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3. European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 "CREATE".en
dc.typeArticleen
dc.contributor.departmentDepartment of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgiumen
dc.identifier.journalAnnals of Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.